Alıntılar

APA (7. basım) Alıntı
Bracchi, M., Pagani, N., Pria, A. D., Milinkovic, A., Nwokolo, N., Thomas, L., . . . Moyle, G. (2021). A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients. Taylor & Francis Group.
Chicago Style (17. basım) Atıf
Bracchi, Margherita, Nicole Pagani, Alessia Dalla Pria, Ana Milinkovic, Nneka Nwokolo, Lervina Thomas, Sundhyia Mandalia, Marta Boffito, ve Graeme Moyle. A Phase IV, Open-label Three-arm Study Investigating the Impact of a Combination of Tenofovir Disoproxil Fumarate/emtricitabine with Raltegravir or Dolutegravir or Elvitegravir/cobicistat on Renal Function in HIV-1 Antiretroviral Naïve Patients. Taylor & Francis Group, 2021.
MLA (9th ed.) Atıf
Bracchi, Margherita, et al. A Phase IV, Open-label Three-arm Study Investigating the Impact of a Combination of Tenofovir Disoproxil Fumarate/emtricitabine with Raltegravir or Dolutegravir or Elvitegravir/cobicistat on Renal Function in HIV-1 Antiretroviral Naïve Patients. Taylor & Francis Group, 2021.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..